Breast cancer (BC) is one of the most widely diagnosed cancers and a leading cause of
cancer death among women worldwide. Globally, BC is the second most frequent cancer …

The success of inhibitor-based therapeutics is largely constrained by the acquisition of
therapeutic resistance, which is partially driven by the undruggable proteome. The …

Targeted degradation of the cell-surface and extracellular proteins via the endogenous
lysosomal degradation pathways, such as lysosome-targeting chimeras (LYTACs), has …

Proteolysis-targeting chimera (PROTAC) technology has emerged as a potential strategy to
degrade “undruggable” proteins in recent years. Nrf2, an aberrantly activated transcription …

We propose the introduction of the azido and azo-functionalities into prenylated derivatives
under mild conditions in a selective and efficient way. Upon protocol establishment and …

The aggregation of specific proteins is a histopathological hallmark in various
neurodegenerative diseases (NDs), among which Alpha-synuclein (α-Syn) and tau have …

Imbalances in protein and noncoding RNA levels in vivo lead to the occurrence of many
diseases. In addition to the use of small molecule inhibitors and agonists to restore these …

The scientific community has shown considerable interest in proteolysis-targeting chimeras
(PROTACs) in the last decade, indicating their remarkable potential as a means of achieving …

The introduction of biologically relevant organic moieties in the coordination sphere of
transition metal complexes has recently become a well-established strategy to increase the …

By introducing a therapeutic nucleoside analogue tail to the parent Aptamer-PROTACs, a
PROTAC-cocktail system (ApTCs-3X) was designed and evaluated. ApTCs-3X exhibited …